3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
6
Leukemia
2
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
pirtobrutinib
6
Cyclophosphamide
6
Mycophenolic Acid
5
fludarabine phosphate
4
fludarabine
4
Rituximab
4
Melphalan
4
Azacitidine
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Tacrolimus
3
Mesna
3
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Lenalidomide
2
Cyclosporine
2
Busulfan
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Bendamustine Hydrochloride
2
zanubrutinib
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
cedazuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Arsenic Trioxide
×
1 year
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled